Progress in the application of poly ADP-ribose polymerase inhibitors in tumor radiotherapy
10.3760/cma.j.issn.0254-5098.2021.10.013
- VernacularTitle:聚腺苷二磷酸核糖聚合酶抑制剂在肿瘤放射治疗中的应用研究进展
- Author:
Fuzhen ZHAO
1
;
Lijun HU
;
Jingping YU
Author Information
1. 大连医科大学研究生院 116000
- Keywords:
PARP inhibitors;
Radiation therapy;
Malignant tumors
- From:
Chinese Journal of Radiological Medicine and Protection
2021;41(10):796-800
- CountryChina
- Language:Chinese
-
Abstract:
The poly ADP-ribose polymerase (PARP) is a class of nuclear enzymes highly expressed in eukaryotic cells and plays a key role in DNA damage repair. In recent years, PARP inhibitors have shown great potential in tumor therapy, and several PARP inhibitors have been approved by the FDA for maintenance therapy of a variety of cancers. PARP inhibitors mainly inhibit PARP enzymes and PARP trapping, resulting in the persistence of DNA single strand breaks, which are converted to double strand breaks during DNA replication. Studies have shown that PARP inhibitors not only have a significant anti-tumor effect, but also have a synergistic effect with radiotherapy. This paper reviewed the potential theoretical basis of PARP inhibitor combined with radiotherapy, summarized the recent progress of preclinical and clinical research on PARP inhibitors in tumor radiotherapy, sorted out the urgent problems in this field, and looked into the application prospect of PARP inhibitors in anti-tumor therapy.
